Guggenheim on Praxis Precision Medicines (PRAX): one of our Top Picks for 2026
Tweet Send to a Friend
Guggenheim analyst Yatin Suneja reiterated a Buy rating and $760.00 price target on Praxis Precision Medicines Inc. (NASDAQ: PRAX).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
